Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Specimen Handling 80Fluorouracil 74Oxaliplatin 69Magnetic Resonance Spectroscopy 61Leucovorin 58Gemcitabine 55Bevacizumab 55Biopsy 41Capecitabine 40Irinotecan 37Cisplatin 36Nivolumab 35pembrolizumab 33Cetuximab 33durvalumab 30Paclitaxel 27130-nm albumin-bound paclitaxel 27atezolizumab 20Folfox protocol 20Radiotherapy 17Carboplatin 17dehydroftorafur 15Taxes 15Cyclophosphamide 15fludarabine 13X-Rays 13Radiation 13trastuzumab deruxtecan 12Surgical Procedures, Operative 12Albumin-Bound Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
berzosertib × Gastrointestinal × 30 days × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡